To view this notification widget you need to have JavaScript enabled. This notification widget was easily created with NotifySnack.
  Loading... Please wait...


Our Newsletter


Arterial Disease, Angina, Blood Clots, Deep Vein Thrombosis DVT

Arteriosclerosis (calcium deposits) and Atherosclerosis (fat deposits) involve a build-up on the inside of artery walls.

While there is overwhelming evidence that high levels of cholesterol increases the risk of developing Atherosclerosis, Angina, DVT and Blood Clots, cholesterol is not the damaging mechanism. Measuring the proportional relationship between HDL cholesterol and LDL cholesterol more accurately assesses the risk of atherosclerosis. The latest research shows that inflammation and free radicals cause damage to both the cholesterol and artery walls that initiates a natural repair sequence that results in the patching and build-up of calcium and cholesterol deposits. The marker that I believe will become the gold standard for risk isHomocysteine. This relates to cardiovascular risk in a much more precise way than cholesterol. A simple blood test indicates the risk and can be re-measured after a nutritional program to ascertain the effectiveness of the program.

This program shows that controlling free radicals is a more successful angle for preventing this major cardiovascular disease problem. This has more potential to provide much greater success than restrictive fat and cholesterol diets that have thus far failed.

How can Serracor-NK and Serra RX80 help?

Nattokinase - a well studied enzyme, famous for dissolving blood clots faster than any drug.

Nattokinase Research - Fibrinoyltic Activity

In vitro and in vivo studies have consistently demonstrated the potent fibrinolytic effect of Nattokinase.1 Research with nattokinase demonstrates that it may help avoid or reduce the likelihood of deep vein thrombosis, cardiac infarction, pulmonary emboli and stroke. It appears to accomplish this via its finbrinolytic, anti-inflammatory and modulating effect on blood pressure. Studies on hypertension demonstrate an average drop of 10.9% in Systolic Blood Pressure and a 9.7 percent drop in Diastolic Blood Pressure.2,3,4

A study conducted with natto on 12 healthy adults (6 men and 6 women, between the ages of 21 and 55) sought to demonstrate fibrinolytic activity. The volunteers were given 200 grams of natto (the food) before breakfast, then their fibrinolytic activity was tested over time. The results indicate natto generates an increased ability to dissolve blood clots. As a control, researchers later fed the same amount of boiled soybeans to the same volunteers and tracked their fibrinolytic activity. The tests showed no significant change.5

The accumulation of fibrin in blood vessels significantly increases the likelihood of thrombosis formation resulting in a cardiovascular event. For thrombolytic therapy, microbial fibrinolytic enzymes are now much more accepted. The physiochemical properties of this enzyme is becoming well characterized and its effectiveness in thrombolysis in vivo has been further identified.6,7


Blood clots (thrombi) form when strands of fibrin accumulate in the circulatory system. These clots can cause blockage of blood flow. If blood flow is blocked, the oxygen supply to that tissue is cut off and it eventually dies. In the heart, this can result in myocardial infarction (heart attack). In the brain, it can result in strokes or mini-strokes. Deep vein thrombosis can result in pulmonary emboli. All these events can be life-threatening. An in vitro study not only demonstrated the powerful fibrinolytic activity of nattokinase, but also showed the significant reduction in the aggregation of red blood cells and overall lowered whole blood viscosity. The net results are vascular conditions that are less likely to produce blood clots. The authors suggest that nattokinase possesses very real potential as a therapeutic agent in cardiovascular health.8

The process of forming a clot is complex and involves several enzymes. However, the body mainly produces one central enzyme for dissolving a clot, plasmin. It happens that the properties of nattokinase are very similar to plasmin. Nattokinase is particularly effective because it enhances the body's natural ability to fight blood clots in several different ways. It dissolves fibrin directly and appears to enhance the body's natural production of both plasmin and other clot-dissolving enzymes like urokinase. An in vivo study was undertaken to demonstrate the thrombolytic activity of nattokinase, plasmin and elastase on an induced clot in the common carotid artery of laboratory rats. The results indicate that the thrombolytic activity of nattokinase is stronger than that of plasmin or elastase in vivo in this model.9

A fascinating study was conducted to measure the effect of nattokinase in the prevention of deep vein thrombosis and superficial vein thrombosis on extended flights of 7-8 hours on high-risk individuals. The nattokinase group had no thromboses. The placebo group had 5 deep vein thromboses and 2 superficial vein thromboses or 7.6% of 94 individuals. After the flight, the degree of edema was increased by 12% in the placebo group and decreased by 15% in the nattokinase group. The authors concluded that nattokinase was effective in reducing thrombotic events and in controlling edema in high-risk subjects on long flights.10


Understanding Fibrin

Fibrin is an insoluble protein the body produces in response to bleeding or inflammation. Fibrin performs important functions in the body, including clotting and wound healing. During the blood clotting process, the protein precursor fibrinogen is converted into fibrin, which forms a layer of connective tissue inside the damaged blood vessel. To do this, the fibrin strands assemble into a net-like structure over the damaged vessel and harden, forming a “patch” or small clot to prevent further damage.3
Despite its protective function, excessive fibrin can do more harm than good. A high level of circulating fibrin has the potential to accelerate scarring, increase clot formation and impede normal blood flow. This can lead to increased blood viscosity, swelling, edema, pain, chronic inflammation and more serious fibrotic conditions or cardiovascular events.3
According to Scripps Research Institute, “It is generally assumed that the persistence of fibrin in the extra cellular matrix (connective tissue) promotes fibrosis, and that the extent of fibrosis is limited by proteases (protein-digesting enzymes) that remove the fibrin. Fibrotic disease occurs when normal control of this process is compromised and excess fibrous material accumulates in the tissues.”

Serracor-NK for Circulatory & Inflammation Support

Serracor-NK contains SEBkinase® with enteric coated serrapeptase and nattokinase, as found in the original Neprinol® formula. We are the original manufacturer of this formula, imitated by many others (to learn more about Serracor-NK vs. Neprinol, please click the "Compare" tab).
SEBkinase brings together two enteric coated, fibrinolytic proteases: Peptizyme-SP® (Serrapeptase) and NattoSEB® (our Nattokinase is Vitamin K-free, since it assists in blood coagulation). Serracor NK further supports the activity of SEBkinase-CV with a complete array of proteolytic enzymes, amylase, lipase, CoQ10, herbs and minerals. The net result is a comprehensive systemic enzyme blend designed to support maximum circulatory health.2
Serracor-NK also promotes healthy levels of C-reactive protein (CRP), an inflammation marker for inflammation and cardiovascular health.1 In addition, the entire systemic enzyme blend is manufactured in a ISO 9001:2000 and GMP certified facilities using our Bioactive Protein Peptide System® (BPPS).

Enteric coated Serrapeptase and Nattokinase: Why is it important?

Most nattokinase and serrapeptase brands on the market are not enteric coated, which means they can lose a significant portion of their fibrinolytic activity and effectiveness in the acidic environment of the stomach. The enteric coating of our Serracor-NK SEBkinase blend allows these sensitive enzymes to survive the acidic conditions of the stomach, thus allowing them to pass into the circulatory system maintaining high activity levels.
The pH resistant enteric coating will disintegrate after it enters the alkaline environment of the intestines. If your enzyme formula is not enteric coated, you may be wasting your money (to learn more about enteric coating used in AST Enzymes products, please click the"Compare" tab).

How do Fibrinolytic Units (FU's) relate to enteric coating?

Enzyme activity measured in fibrinolytic units does not mean anything if the enzymes are destroyed and/or denatured in the high acidic conditions of the stomach. Under these conditions, our laboratory tests have consistently shown that serrapeptase and nattokinase lose significant activity when exposed to low pH (such as those in the stomach). In contrast, our enteric coated nattokinase and serrapeptase (the original SEBkinase formula) perform at greater activity levels in the same low pH conditions.

Enzyme Stabilization with BPPS®

The Bioactive Protein Peptides System (BPPS) is a system of peptides used to stabilize and enhance the activity of enzymes.
The Bioactive Protein Peptides System was developed by Specialty Enzymes and Biotechnologies (SEB) specifically for enzyme stability. Stabilizers have been used since SEB began manufacturing enzymes in 1957. The BPPS system was a significant advancement developed by SEB in the early 1990's.

It is true it was not trademarked until 2008, but it was in use long before. The reality is: a pure enzyme is not stable. It requires the addition of stabilizers in order to provide a reasonable shelf life. Because we are the actual manufacturer of enzymes with more than 50 years of manufacturing experience, our research and development team constantly works to improve stability and tolerance to the environments in which the enzymes interact. Marketing companies, on the other hand, will generally have significantly less understanding of the physio-chemical and kinetic properties of enzymes. Read More On Serracor-NK

Serracor-NK Dosage

For best results, begin enzyme regiment at a low dosage of 1 capsule three times a day. After three days, increase your Serracor-NK dosage to 2 capsules three times a day. After the first week, doses should be adjusted to a therapeutic level of 3 or more capsules three times a day (amount is dependent upon desired benefit).

NOTE: It is important to continue therapeutic doses until results are realized. This should then be reduced to a maintenance dose of 1-3 capsules three times a day.

Complementing your Serracor-NK with additional serrapeptase can support fibrin levels, as well as support a therapeutic internal balance.
Serra RX 80 contains 80,000 units of professional-strength serrapeptase per capsule.


An enzyme derived from a species of bacteria originally found in the intestine of silkworms. The bacteria, Serratia mercesans produces the enzyme that enables the silkworm to dissolve its silken cocoon and emerge after metamorphosis. Serratia is now grown in cultures to produce serrapeptase by fermentation. Numerous research and clinical studies demonstrate serrapeptase's formidable anti-inflammatory, proteolytic (protein dissolving) and fibrinolytic (fibrin dissolving) properties. They also show that scar tissue is greatly reduced and proteins involved in the inflammatory process are effectively digested. Serrapeptase is a protease that has been used in Japan and Europe for over four decades for its anti-inflammatory activity. Read More On Serra RX80

Hardened Arteries Show Improvement

Even healthy adults can reduce the risk of heart attack by taking fibrinolytic enzymes such as Nattokinase and Serrapeptase. Unlike taking daily aspirin, Serracor-NK thins the blood, removes unwanted debris, has no gastrointestinal side effects, and does not put stress on the liver. As little as 3 pills per day may greatly reduce the risk of heart attack. For those already effected by heart disease, fibrinolytic enzymes have the amazing ability to emulsify arterial plaque, remove scar tissue, and lower LDL cholesterol throughout the body. Nattokinase has been clinically tested to remove arterial blockages 60% faster than the body's natural fibrinolytic enzyme plasmin. The addition of Serrapeptase allows Serracor-NK to fight inflammation and cardiovascular blockages in 2 distinct ways.

Heart disease is the number one killer in the US. Hardening of the arteries occurs over time, so your risk increases as you age. The condition is most common in middle-aged and older adults. Your risk of developing this disease also increases if you suffer from one of the following conditions, We strongly urge you to seriously consider making Serracor-NK and SerraRX 80 a daily part of your health regimen:

  • You have had a heart attack or stroke
  • You have Diabetes
  • You experience pain or muscle fatigue when you walk short distances 
  • Trouble managing stress
  • You suffer from muscle aches or "restless legs"
  • Your hands and feet frequently fall "asleep" or feel tingly
  • You have chronic kidney disease

You are or have been diagnosed with atherosclerosis, heart disease, hypertension, angina, or other cardiovascular problems and are taking any type of heart or blood pressure medication or have a family history of early heart disease.

Serracor-NK is composed of Pharmaceutical-grade ingredients, provided exclusively through licensed healthcare practitioners and supplementation outlet stores. Serracor-NK is 100% natural and contains no animal derivatives it is available now without a prescription.

***Serracor-NK is safe to use with all supplements and all prescription medication except for prescription blood-thinners and anticoagulants such as Coumadin and Heparin.****


1. Pais E, Alexy T, Holsworth RE Jr, Meise HJ. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35:139-142.
2. C.-H. Hsia et al. / Nutrition Research 29 (2009) 190-196.
3. John D. Ferryand Peter R. Morrison. Chemical, Clinical and Immunological Studes On The Products of Human Plasma Fractionation. XVI. Fibrin Clots, Fibrin Films, and Fibrongen Plastics.


* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Results may vary.  Copyright © 2004 Biomedic Labs. All rights reserved Terms & Conditions